Skip to main content

Advertisement

Table 1 Recurrent thrombosis in the patients with antiphospholipid antibodies

From: Controversies in the antiphospholipid syndrome: can we ever stop warfarin?

Study design N Mean age Years Entry criteria Patient Characteristics Mean Follow up Years Patients with recurrent events No. (%) Number of recurrent events All (arterial/venous) Reference
Retrospective 70 48W 22M 45.5 ± 17.3 aPL (aCL/LA) + arterial/venous thrombosis (1st event) PAPS 51 SLE 14 ITP 5 5.2 37/70 (53%) 54 Rosove MH et al. Ann Intern Med 1992
Retrospective 19 16W 3M 26 (15–40) aPL (aCL/LA) + venous thrombosis (1st event) PAPS 1 SLE 12 Lupus like 6 8 12/19 (63%) 37 (3/34) Derksen R et al. Ann Rheum Dis 1993
Retrospective 147 124W 23M 32 (14–66) aPL (aCL/LA) + arterial/venous thrombosis (1st event) PAPS 62 SLE 66 Lupus like 19 7 101/147 (69%) 186 (75/111) Khamashta M et al. N Eng J Med 1995
Prospective 360 242W 118M 39 (2–78) aPL (aCL/LA) (117 aPL pt with previous arterial/venous thrombosis) SLE 69 Lupus like 66 4 25/117 (21.3%) 25 Finazzi G et al. Am J Med 1996
Prospective 412 181W 231M 60.2 Venous thrombosis (1st event) allocated 6 months warfarin - 4 20/68 aCL+ (29%) 47/344 aCL- (14%) 67 (-/67) Schulman S et al. Am J Med 1998
Prospective 56 48W 8M 37 ± 10 APS (aPL + thrombosis and/or fetal loss) (43 patients with previous arterial/venous thrombosis) PAPS only 5 14/43 (32.5) 16 (10/6) Turiel M et al. Stroke 2005
  1. W – women; M – men; aPL – antiphospholipid antibodies; aCL – anticardiolipin antibodies; LA – lupus anticoagulant; PAPS – primary antiphospholipid syndrome; SLE – systemic lupus erytematosus; Lupus like – Lupus like disease; ITP – chronic idiopathic thrombocytopenic purpura.